The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Reevaluation of interaction of cis-dichloro(ethylenediamine)platinum(II) with DNA
Abstract
Intrastrand cross-links represent the majority of modifications in DNA resulting from interaction with the cancer chemotherapeutic drug cis-diamminedichloroplatinum(II) (cis-DDP). These adducts were recently characterized although several discrepancies remained to be resolved. In these studies, [3H]-cis-dichloro(ethylenediamine)platinum(II) (cis-DEP) was used because of the convenience of the radiolabel; this analogue produces adducts at identical sites in DNA as cis-DDP. Both drugs platinate the following sequences in DNA: GG, 65%; AG, 25%; GNG, 6%. The adduct at AG sequences invariably has adenine on the 5'-terminus of the dimer. The present enzyme digestion protocol included P1 nuclease, which produced complete digestion rather than as previously reported. The frequency of platination at GG was too high to be explained by an initial monofunctional platination at any guanine. However, direct bifunctional attack preferentially at GG was obviated because monofunctional adducts could be trapped with thiourea at short time periods. After short incubations, with cis-DEP and removal of unreacted drug, the monofunctional adducts slowly rearranged to bifunctional adducts. It is suggested that this evolution of adducts may result from the drug "walking" along the double helix, a phenomenon that does not appear to occur in single-stranded DNA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fichtinger-Schepman, A. M. J., Van der Veer, J. L., Den Hartog, J. H. J., Lohman, P. H. M., & Reedijk, J. (1985) · Biochemistry · doi:10.1021/bi00324a025 · Cited by 1,024
The Mechanism of Action of Antitumor Platinum Compounds
Roberts, J. J., & Thomson, A. J. (1979) · Progress in Nucleic Acid Research and Molecular Biology · doi:10.1016/s0079-6603(08)60799-0 · Cited by 411
Royer‐Pokora, B., Gordon, L. K., & Haseltine, W. A. (1981) · Nucleic Acids Research · doi:10.1093/nar/9.18.4595 · Cited by 144
Eastman, A. R. (1985) · Biochemistry · doi:10.1021/bi00340a011 · Cited by 142
Self-citationTullius, T. D., & Lippard, S. J. (1981) · Journal of the American Chemical Society · doi:10.1021/ja00405a073 · Cited by 90
Cited by
Structure, Recognition, and Processing of Cisplatin−DNA Adducts
Jamieson, E. R., & Lippard, S. J. (1999) · Chemical Reviews · doi:10.1021/cr980421n · Cited by 2,949
DNA interstrand crosslink repair and cancer
Deans, A. J., & West, S. C. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3088 · Cited by 1,023
Exploration of the medical periodic table: towards new targets
Barry, N. P. E., & Sadler, P. J. (2013) · Chemical Communications · doi:10.1039/c3cc41143e · Cited by 717
Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair.
Chu, G. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)42175-2 · Cited by 651
Oxaliplatin: A review of preclinical and clinical studies
Raymond, E., Chaney, S. G., Taamma, A., & Cvitkovic, E. (1998) · Annals of Oncology · doi:10.1023/a:1008213732429 · Cited by 643
Eastman, A. (1987) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(87)90009-x · Cited by 539
Self-citationInhibition of transcription by platinum antitumor compounds
Todd, R. C., & Lippard, S. J. (2009) · Metallomics · doi:10.1039/b907567d · Cited by 539
Cisplatin Induces Endoplasmic Reticulum Stress and Nucleus-independent Apoptotic Signaling
Mandic, A., Hansson, J., Linder, S., & Shoshan, M. C. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210284200 · Cited by 509
Advances in Toxicological Research of the Anticancer Drug Cisplatin
Qi, L., Luo, Q., Zhang, Y., Jia, F., Zhao, Y., & Wang, F. (2019) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.9b00204 · Cited by 440
Duckett, D. R., Drummond, J. T., Murchie, A. I., Reardon, J. T., Sancar, A., Lilley, D. M., & Modrich, P. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.13.6443 · Cited by 421
Carbon Nanohorns as Anticancer Drug Carriers
Ajima, K., Yudasaka, M., Murakami, T., Maigné, A., Shiba, K., & Iijima, S. (2005) · Molecular Pharmaceutics · doi:10.1021/mp0500566 · Cited by 411
Crystal Structure of the Anticancer Drug Cisplatin Bound to Duplex DNA
Takahara, P. M., Frederick, C. A., & Lippard, S. J. (1996) · Journal of the American Chemical Society · doi:10.1021/ja9625079 · Cited by 405
Cellular and molecular determinants of cisplatin resistance
Perez, R. P. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00227-5 · Cited by 384
Cisplatin Binding Sites on Human Albumin
Ivanov, A. I., Christodoulou, J., Parkinson, J. A., Barnham, K. J., Tucker, A., Woodrow, J., & Sadler, P. J. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.24.14721 · Cited by 362
The influence of structure on the activity and toxicity of Pt anti-cancer drugs
Hambley, T. W. (1997) · Coordination Chemistry Reviews · doi:10.1016/s0010-8545(97)00023-4 · Cited by 348
Enhanced DNA repair as a mechanism of resistance to cis-diamminedichloroplatinum(II)
Eastman, A., & Schulte, N. (1988) · Biochemistry · doi:10.1021/bi00413a022 · Cited by 312
Self-citationDrummond, J. T., Anthoney, A., Brown, R., & Modrich, P. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.33.19645 · Cited by 295
Baik, M.-H., Friesner, R. A., & Lippard, S. J. (2003) · Journal of the American Chemical Society · doi:10.1021/ja036960d · Cited by 293
Bellon, S. F., Coleman, J. H., & Lippard, S. J. (1991) · Biochemistry · doi:10.1021/bi00246a021 · Cited by 291
Inhibition of RNA polymerase II as a trigger for the p53 response
Ljungman, M., Zhang, F., Chen, F., Rainbow, A. J., & McKay, B. C. (1999) · Oncogene · doi:10.1038/sj.onc.1202356 · Cited by 288
DNA Repair: Enzymatic Mechanisms and Relevance to Drug Response
Chaney, S. G., & Sancar, A. (1996) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/88.19.1346 · Cited by 280
Lukin, M., & de los Santos, C. (2006) · Chemical Reviews · doi:10.1021/cr0404646 · Cited by 158
Metadata
- Authors
- Eastman, A.
- Venue
- Biochemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 1986-07-01
- Volume
- 25
- Issue
- 13
- Pages
- 3912-3915
- ISSN
- 0006-2960 (ISSN-L)
- 1520-4995
- OpenAlex
- W1976874431
- Cited by
- 458
- References
- 5
- FWCI
- 8.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.